Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and ...

Structure Therapeutics (GPCR) Gained from Favorable Clinical Data

Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap ...
Yahoo Finance

Structure Therapeutics Inc. (GPCR) Has Gained Over 130% in 3 Months. Here is Why

Structure Therapeutics Inc. (NASDAQ:GPCR) is among the 14 best booming stocks to buy right now. The company’s shares have gained over 130% in the past three months, with a major surge since early ...

Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?

Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivals’ setbacks. Click here ...

SEP-631 Phase 1 Readout: The Catalyst Set To Drive Septerna In 2026

Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...
Nasdaq

Interesting GPCR Put And Call Options For December 2026

Investors in Structure Therapeutics Inc (Symbol: GPCR) saw new options begin trading today, for the December 2026 expiration. One of the key data points that goes into the price an option buyer is ...
Technology Networks

Researchers Uncover Thermodynamic Trade-Off in GPCR Drug Binding

Researchers analyzed the thermodynamics of doxepin binding to the histamine H1 receptor. The findings highlight the ...
Business Wire

Septerna to Present Preclinical Data from GPCR Drug Discovery Engine at ENDO 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, a biotechnology company discovering and advancing novel, oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today ...